Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer

Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer

Osimertinib is first-line treatment for epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has been associated with cardiotoxicity. However, the nature of cardiac remodeling and associated risk factors remains incompletely understood. Retrospective analysis of NSCLC patien...

Descrición completa

Detalles Bibliográficos
Main Authors: Jonathan N. Le, Jordan O. Gasho, Olivia Peony, Asneh Singh, Katrina D. Silos, Sungjin Kim, Anthony T. Nguyen, Mitchell Kamrava, Amin Mirhadi, Behrooz Hakimian, Karen L. Reckamp, Kamya Sankar, Raymond H. Mak, Andriana P. Nikolova, Katelyn M. Atkins
Formato: Artigo
Idioma:English
Publicado: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
osimertinib
lung cancer
cardiac toxicity
echocardiogram
EGFR
Acceso en liña:https://www.frontiersin.org/articles/10.3389/fcvm.2024.1485033/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2024.1485033/full

Títulos similares